Moderna Inc (MRNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $90.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Moderna Inc (MRNA) Earnings: Report Dates and Results
Moderna (MRNA) is expected to report earnings on Feb 11, 2027. In the quarter ended Sep 30, 2026, Moderna reported EPS of $0.38, above the -$1.10 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MRNA has an expected report date of Feb 11, 2027.
MRNA Earnings Call
The latest MRNA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 32 quarters below that had an estimate, MRNA beat 21, missed 10 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.31B, up 28.4% from $1.02B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.38 | -$1.10 | -$3.28 - -$0.80 | +134.55% | Beat | N/A | 16 | 5 up, 3 down | Nov 6, 2026 | $1.31B |
| Jun 30, 2026 | -$1.97 | -$1.97 | -$2.35 - -$1.80 | 0.00% | In line | N/A | 15 | N/A | Jul 31, 2026 | $145.00M |
| Mar 31, 2026 | -$3.40 | -$2.11 | -$4.65 - -$1.86 | -61.14% | Miss | N/A | 12 | 1 up, 2 down | May 1, 2026 | $389.00M |
| Dec 31, 2025 | -$2.11 | -$2.64 | -$3.23 - -$2.10 | +20.08% | Beat | N/A | 13 | 2 up, 2 down | Feb 13, 2026 | $678.00M |
| Sep 30, 2025 | -$0.51 | -$2.16 | -$3.10 - -$1.31 | +76.39% | Beat | -1800.0% | 14 | 2 up, 2 down | Nov 6, 2025 | $1.02B |
| Jun 30, 2025 | -$2.13 | -$3.00 | -$3.58 - -$2.63 | +29.00% | Beat | N/A | 12 | 0 up, 2 down | Aug 1, 2025 | $142.00M |
| Mar 31, 2025 | -$2.52 | -$3.11 | -$3.60 - -$2.91 | +18.97% | Beat | N/A | 12 | 1 up, 2 down | May 1, 2025 | $108.00M |
| Dec 31, 2024 | -$2.91 | -$2.76 | -$3.37 - -$1.05 | -5.44% | Miss | -629.1% | 14 | 2 up, 4 down | Feb 14, 2025 | $966.00M |
| Sep 30, 2024 | $0.03 | -$1.90 | -$2.58 - -$1.33 | +101.58% | Beat | N/A | 16 | 3 up, 0 down | Nov 7, 2024 | $1.86B |
| Jun 30, 2024 | -$3.33 | -$3.35 | -$4.20 - -$2.93 | +0.60% | Beat | N/A | 16 | 0 up, 1 down | Aug 1, 2024 | $241.00M |
| Mar 31, 2024 | -$3.07 | -$3.57 | -$4.32 - -$3.03 | +14.01% | Beat | -1715.8% | 15 | 0 up, 0 down | May 2, 2024 | $167.00M |
| Dec 31, 2023 | $0.55 | -$0.97 | -$2.64 - $3.13 | +156.70% | Beat | -84.8% | 17 | 4 up, 0 down | Feb 22, 2024 | $2.81B |
| Sep 30, 2023 | -$9.53 | -$2.05 | -$3.45 - -$0.62 | -364.88% | Miss | -476.7% | 14 | N/A | Nov 2, 2023 | $1.83B |
| Jun 30, 2023 | -$3.62 | -$4.12 | -$4.62 - -$3.01 | +12.14% | Beat | -169.1% | 15 | 2 up, 0 down | Aug 3, 2023 | $344.00M |
| Mar 31, 2023 | $0.19 | -$1.77 | -$3.61 - -$0.70 | +110.73% | Beat | -97.8% | 14 | 3 up, 1 down | May 4, 2023 | $1.86B |
| Dec 31, 2022 | $3.61 | $4.60 | $3.75 - $5.56 | -21.52% | Miss | -68.0% | 14 | 2 up, 0 down | Feb 23, 2023 | $5.08B |
| Sep 30, 2022 | $2.53 | $3.11 | $1.77 - $5.39 | -18.65% | Miss | -67.1% | 13 | 1 up, 3 down | Nov 3, 2022 | $3.36B |
| Jun 30, 2022 | $5.24 | $4.49 | $2.02 - $5.34 | +16.70% | Beat | -18.9% | 13 | 0 up, 1 down | Aug 3, 2022 | $4.75B |
| Mar 31, 2022 | $8.58 | $5.62 | $1.89 - $7.72 | +52.67% | Beat | +202.1% | 12 | 2 up, 2 down | May 4, 2022 | $6.07B |
| Dec 31, 2021 | $11.29 | $9.90 | $5.25 - $10.85 | +14.04% | Beat | N/A | 11 | 0 up, 0 down | Feb 24, 2022 | $7.21B |
| Sep 30, 2021 | $7.70 | $9.42 | $6.98 - $11.01 | -18.26% | Miss | N/A | 11 | N/A | Nov 4, 2021 | $4.97B |
| Jun 30, 2021 | $6.46 | $5.86 | $3.27 - $8.12 | +10.24% | Beat | N/A | 12 | N/A | Aug 5, 2021 | $4.35B |
| Mar 31, 2021 | $2.84 | $2.47 | $0.82 - $5.56 | +14.98% | Beat | N/A | 12 | N/A | May 6, 2021 | $1.94B |
| Dec 31, 2020 | -$0.69 | -$0.35 | -$0.82 - $0.17 | -97.14% | Miss | N/A | 12 | N/A | Feb 25, 2021 | $571.00M |
| Sep 30, 2020 | -$0.59 | -$0.37 | -$0.95 - -$0.23 | -59.46% | Miss | N/A | 12 | N/A | Oct 29, 2020 | $157.00M |
| Jun 30, 2020 | -$0.31 | -$0.36 | -$0.53 - -$0.22 | +13.89% | Beat | N/A | 12 | N/A | Aug 5, 2020 | $67.00M |
| Mar 31, 2020 | -$0.35 | -$0.36 | -$0.39 - -$0.28 | +2.78% | Beat | N/A | 10 | N/A | May 7, 2020 | $8.00M |
| Dec 31, 2019 | -$0.37 | -$0.42 | -$0.45 - -$0.40 | +11.90% | Beat | N/A | 8 | N/A | Feb 26, 2020 | $13.85M |
| Sep 30, 2019 | -$0.37 | -$0.44 | -$0.46 - -$0.39 | +15.91% | Beat | N/A | 6 | N/A | Nov 6, 2019 | $17.05M |
| Jun 30, 2019 | -$0.41 | -$0.45 | -$0.47 - -$0.40 | +8.89% | Beat | N/A | 5 | N/A | Aug 7, 2019 | $13.08M |
| Mar 31, 2019 | -$0.40 | -$0.36 | -$0.45 - -$0.25 | -11.11% | Miss | N/A | 7 | N/A | May 9, 2019 | $16.02M |
| Dec 31, 2018 | -$1.78 | -$0.36 | -$0.45 - -$0.20 | -394.44% | Miss | N/A | 7 | N/A | Mar 6, 2019 | $35.42M |
| Sep 30, 2018 | -$0.52 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 7, 2018 | $41.76M |
| Jun 30, 2018 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2018 | $28.85M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$7.27, after -$9.28 the year before. It was -$2.59 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$7.27 | N/A |
| Dec 31, 2024 | -$9.28 | N/A |
| Dec 31, 2023 | -$12.41 | -162.2% |
| Dec 31, 2022 | $19.96 | -29.4% |
| Dec 31, 2021 | $28.29 | N/A |
| Dec 31, 2020 | -$1.94 | N/A |
| Dec 31, 2019 | -$1.55 | N/A |
| Dec 31, 2018 | -$2.59 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,432 | 18 | |
| 2026Q2 | Jun 30, 2026 | 8,411 | 17 | |
| 2026Q1 | Mar 31, 2026 | 6,872 | 18 | |
| 2025Q4 | Dec 31, 2025 | 8,385 | 7 | |
| 2025Q3 | Sep 30, 2025 | 6,963 | 15 | |
| 2025Q2 | Jun 30, 2025 | 8,765 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,665 | 12 | |
| 2024Q4 | Dec 31, 2024 | 7,647 | 18 |
2026Q3 Earnings Call
Opening remarks
Lavina Talukdar Head of Investor Relations Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's third quarter 26 financial results and business update. You can access the press release issued this morning, as well as the slides that we will be reviewing, by going to the Investors section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our president; James Mock, our chief financial officer; and David Berman, our chief development officer. Before we begin, please note that this call will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. Please see slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. With that, I will turn the call over to Stéphane.
Stéphane Bancel CEO Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us. We will start today with a review of the third quarter. James will then cover our financial results and outlook, followed by Stephen with our current business updates in infectious diseases. David will then review our clinical progress in oncology and rare diseases. I will come back quickly for a close on our key value drivers before Q&A. The Moderna team delivered a great third quarter, generating $1.4 billion in revenues, representing 29% growth year over year. Importantly, strong commercial performance translated into $200 million in net income for the quarter. We also ended the quarter with a strong balance sheet, with $8 billion in cash and investments, reflecting a combination of solid operational and commercial execution along with a highly successful convertible debt financing. And we continue to demonstrate financial discipline across the company, reducing cash cost by 10% compared to the third quarter of last year. Together, these strong results underscore our ability to deliver strong commercial performance while maintaining financial discipline and strengthening our financial position. During the quarter, we achieved several important milestones across our pipeline and our business. FDA approval of mFLUSIVA, making it Moderna's fifth approved product and the first mRNA-based influenza vaccine to reach the market. In Canada, we secured approvals of both mFLUSIVA and mCOMBRIAX yesterday, the local brand name for mCOMBRIAX, further expanding our respiratory portfolio internationally. In oncology, we are very proud to present positive Phase 3 data for intismeran autogene, our individualized cancer therapy being developed in partnership with Merck. The results demonstrated a significant clinical benefit, with a 42% reduction in the risk of recurrence or death in patients with resected melanoma.
Frequently Asked Questions About MRNA
When is Moderna's next earnings date?
Moderna's next earnings report is expected for Feb 11, 2027.
Did MRNA beat earnings estimates last quarter?
Yes. Moderna reported EPS of $0.38 for the quarter ended Sep 30, 2026, above the -$1.10 estimate, a 134.55% surprise.
What EPS do analysts expect from MRNA next quarter?
The consensus EPS estimate for Moderna for the quarter ending Dec 31, 2026 is -$2.39 from 20 analysts, with estimates from -$4.20 to -$1.78.
How often does MRNA beat earnings estimates?
Moderna beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +26.55%.
MRNA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors